Crossmark

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

Crossref DOI link: https://doi.org/10.1186/s13058-021-01464-1

Published Online: 2021-08-23

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Romine, Perrin E.

Peterson, Lanell M. https://orcid.org/0000-0002-1613-5909
Kurland, Brenda F.

Byrd, Darrin W.

Novakova-Jiresova, Alena

Muzi, Mark

Specht, Jennifer M.

Doot, Robert K.

Link, Jeanne M.

Krohn, Kenneth A.

Kinahan, Paul E.

Mankoff, David A.

Linden, Hannah M. https://orcid.org/0000-0001-5048-2819
Funding

Funding for this research was provided by:

National Cancer Institute (RC1CA146456, P01CA042045, R50 CA211270)

Susan G. Komen (KG100258, SAC130060)

Medical Center, University of Pittsburgh (P30CA047904)
License Information

Text and Data Mining valid from 2021-08-23

Version of Record valid from 2021-08-23
More Information

Article History

Received: 24 May 2021

Accepted: 10 August 2021

First Online: 23 August 2021

Declarations

:

: The studies were approved by the local IRB, and all patients signed an approved, written informed consent.

: Not applicable.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below